Abstract:Background: Anti-IgLON5 disease is a rare autoimmune disease of the central nervous system. It typically manifests as a chronic condition, characterized by cognitive impairments, movement disorders, and sleep disorders. The mechanisms underlying movement disorders in this disease remain poorly understood due to a lack of research. Furthermore, this disease exhibits both neuroimmune and neurodegenerative characteristics. The objective of this study is to explore the underlying mechanisms of movement disorders caused by anti-IgLON5 antibodies for the first time. Methods: Antibodies were purified from the serum of a confirmed patient of anti-IgLON5 disease. The passive transfer animal models were employed, where antibodies were continuously injected into the substantia nigra pars compacta (SNc) of the mouse midbrain using stereotactic injection to explore the mechanism of movement disorder. The effects of anti-IgLON5 antibodies on dopaminergic neurons in the SNc and neurodegeneration were examined through immunohistochemistry. Changes in neurotransmitter levels in the basal ganglia were assessed using high-performance liquid chromatography. Additionally, RNA-seq was employed to identify the differentially expressed genes associated with the short-term and long-term effects of anti-IgLON5 antibody on the SNc. Results: Mice injected with anti-IgLON5 antibodies in the SNc exhibited persistent movement impairments for up to 3 months. One week after antibody injection, the number of TH neurons significantly decreased compared to the control group, accompanied by reduced projection fibers in the basal ganglia and decreased dopamine levels. After 3 months of antibody injection, an increase in phosphorylated Tau was observed in the SNc of the midbrain. Additionally, long-term sustained activation of microglia was detected in the SNc. The differentially expressed genes of long-term effects of IgLON5 antibodies were different from their short-term effects on the SNc. Conclusion: Purified serum IgG from a patient with anti-IgLON5 antibodies can cause long-term movement disorder in mice. The movement disorders appear to be linked to the impaired dopaminergic pathway, and the increased p-Tau showed neurodegenerative changes induced by the anti-IgLON5 antibody.

Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice

Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons

IgLON5 deficiency produces behavioral alterations in a knockout mouse model

Purified Serum IgG from a Patient with Anti-IgLON5 Antibody Cause Long-Term Movement Disorders with Impaired Dopaminergic Pathways in Mice

Clinical presentations and antibody mechanisms in anti-IgLON5 disease

Autoimmune antibody-induced neuronal hyperactivity triggers pathological Tau in IgLON5 disease

Anti-IgLON5 disease: a novel topic beyond neuroimmunology

Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice

Patients’ IgLON5 autoantibodies interfere with IgLON5-protein interactions

New knowledge on anti-IgLON5 disease

Anti-IgLON 5 Disease

Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature

Atypical neurological manifestations in anti-IgLON5 disease: a case report

IgLON5-IgG: Innocent Bystander or Perpetrator?

Case Report: Neuropsychological Findings in IgLON5 Antibody Disorder

Anti-IgLON5 disease exacerbated by asymptomatic SARS-CoV-2 infection

Anti-Iglon5 Disease With Distinctive Brain Mri Findings Responding To Immunotherapy A Case Report

Anti-IgLON5 Disease with intriguing MRI findings respond dramatically to immunotherapy

Anti-IgLON5 disease: A case with intestinal obstruction and peripheral neuropathy

HLA-DQB105 subtypes and not DRB110:01 mediates risk in anti-IgLON5 disease

Expanding the Clinical Spectrum of Anti-Iglon5 Disease: A Multicenter Retrospective Study